PPARG and lung carcinoma: While PPARγ activation in inhibiting lung cancer growth is widely accepted, its role in regulating tumor immunity is controversial, likely due to the complex nature of the tumor microenvironment (TME), which includes cancer cells, stromal cells, endothelial cells, and immune cells like macrophages and myeloid-derived suppressor cells (MDSCs) [63].